Germany's BioNTech to set up centre in Israel to develop medicine, vaccines for cancer


Jerusalem, Mar 23 (IANS): German biotechnology company BioNTech SE will establish a centre in Israel for the development and production of vaccines and drugs against cancer, the Israeli Finance Ministry said in a statement on Wednesday.

The new centre will be set up at the Har-Hotzvim Hi-Tech Park in northwest Jerusalem, in cooperation with the Israeli finance, health and economy ministries, together with the Jerusalem Municipality, Xinhua news agency reported.

The statement noted that the centre will focus on mRNA technologies for treating cancer, and enable better preparation for future pandemics, it added.

 

The German company will also establish an mRNA excellence centre in the central city of Ness Ziona, in cooperation with the nearby Weizmann Institute of Science.

The purpose of the excellence centre is to bring together scientists from Israel's research institutes and hospitals in the fields of life sciences, computer sciences, physics, chemistry, and more, to promote treatment for cancer, infectious diseases, and other diseases.

 

  

Top Stories


Leave a Comment

Title: Germany's BioNTech to set up centre in Israel to develop medicine, vaccines for cancer



You have 2000 characters left.

Disclaimer:

Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.